Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial

Objective: To evaluate the effectiveness of the aromataze inhibitor “letrozole” to progestin “norethisterone” for women with simple endometrial hyperplasia without atypia. Subjects and methods: One hundred women with a histo-pathological diagnosis of simple endometrial hyperplasia without atypia wer...

Full description

Bibliographic Details
Main Authors: M. El-shamy, A. Gibreel, E. Refai, E. Sadek, A. Ragab
Format: Article
Language:English
Published: SpringerOpen 2012-06-01
Series:Middle East Fertility Society Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1110569011001129
id doaj-bede147d999549ca9fa92eaf91555c14
record_format Article
spelling doaj-bede147d999549ca9fa92eaf91555c142020-11-25T02:14:18ZengSpringerOpenMiddle East Fertility Society Journal1110-56902012-06-0117211111510.1016/j.mefs.2011.11.005Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trialM. El-shamyA. GibreelE. RefaiE. SadekA. RagabObjective: To evaluate the effectiveness of the aromataze inhibitor “letrozole” to progestin “norethisterone” for women with simple endometrial hyperplasia without atypia. Subjects and methods: One hundred women with a histo-pathological diagnosis of simple endometrial hyperplasia without atypia were divided into two groups: Groups A and B. Group A included 50 patients who received a daily 5 mg dose of letrozole for three successive months. Group B included the other 50 patients who received norethisterone 10 mg daily by non-stop regimen for 3 months. All patients in both groups were reevaluated after treatment. Women diagnosed with progressive or persistent endometrial hyperplasia at the second curettage were asked to continue on the same medication for another 3 months. Transvaginal sonography as well as serum estradiol level measurement were performed before the start of treatment and 3 months after treatment. Results: Despite that there was no statistically significant difference between the two groups as regards the proportion of women whose endometrial sample revealed resolution, regressing or persistence after 3 months of treatment. However, endometrial thickness was significantly thinner in women who received letrazole than in women who received norethisterone (mean difference 0.12 mm, 95% CI: 0.22–0.01, P = 0.02). Serum E2 level was significantly lower in the Group A compared to Group B (mean difference 9.1 pg, 95% CI: 13.74–4.45, P < 0.001). Conclusion: Letrozole is as effective as norethisterone for women with abnormal uterine bleeding due to endometrial hyperplasia without atypia.http://www.sciencedirect.com/science/article/pii/S1110569011001129Endometrial hyperplasiaLetrozoleProgestin
collection DOAJ
language English
format Article
sources DOAJ
author M. El-shamy
A. Gibreel
E. Refai
E. Sadek
A. Ragab
spellingShingle M. El-shamy
A. Gibreel
E. Refai
E. Sadek
A. Ragab
Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial
Middle East Fertility Society Journal
Endometrial hyperplasia
Letrozole
Progestin
author_facet M. El-shamy
A. Gibreel
E. Refai
E. Sadek
A. Ragab
author_sort M. El-shamy
title Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial
title_short Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial
title_full Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial
title_fullStr Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial
title_full_unstemmed Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial
title_sort aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: a prospective cohort trial
publisher SpringerOpen
series Middle East Fertility Society Journal
issn 1110-5690
publishDate 2012-06-01
description Objective: To evaluate the effectiveness of the aromataze inhibitor “letrozole” to progestin “norethisterone” for women with simple endometrial hyperplasia without atypia. Subjects and methods: One hundred women with a histo-pathological diagnosis of simple endometrial hyperplasia without atypia were divided into two groups: Groups A and B. Group A included 50 patients who received a daily 5 mg dose of letrozole for three successive months. Group B included the other 50 patients who received norethisterone 10 mg daily by non-stop regimen for 3 months. All patients in both groups were reevaluated after treatment. Women diagnosed with progressive or persistent endometrial hyperplasia at the second curettage were asked to continue on the same medication for another 3 months. Transvaginal sonography as well as serum estradiol level measurement were performed before the start of treatment and 3 months after treatment. Results: Despite that there was no statistically significant difference between the two groups as regards the proportion of women whose endometrial sample revealed resolution, regressing or persistence after 3 months of treatment. However, endometrial thickness was significantly thinner in women who received letrazole than in women who received norethisterone (mean difference 0.12 mm, 95% CI: 0.22–0.01, P = 0.02). Serum E2 level was significantly lower in the Group A compared to Group B (mean difference 9.1 pg, 95% CI: 13.74–4.45, P < 0.001). Conclusion: Letrozole is as effective as norethisterone for women with abnormal uterine bleeding due to endometrial hyperplasia without atypia.
topic Endometrial hyperplasia
Letrozole
Progestin
url http://www.sciencedirect.com/science/article/pii/S1110569011001129
work_keys_str_mv AT melshamy aromataseinhibitorletrozoleversusprogestinnorethisteroneinwomenwithsimpleendometrialhyperplasiawithoutatypiaaprospectivecohorttrial
AT agibreel aromataseinhibitorletrozoleversusprogestinnorethisteroneinwomenwithsimpleendometrialhyperplasiawithoutatypiaaprospectivecohorttrial
AT erefai aromataseinhibitorletrozoleversusprogestinnorethisteroneinwomenwithsimpleendometrialhyperplasiawithoutatypiaaprospectivecohorttrial
AT esadek aromataseinhibitorletrozoleversusprogestinnorethisteroneinwomenwithsimpleendometrialhyperplasiawithoutatypiaaprospectivecohorttrial
AT aragab aromataseinhibitorletrozoleversusprogestinnorethisteroneinwomenwithsimpleendometrialhyperplasiawithoutatypiaaprospectivecohorttrial
_version_ 1724900528720183296